**Author details**

Ana João Pissarra1†, Catarina Abreu1†, André Mansinho1,2, Ana Lúcia Costa1 , Sara Dâmaso<sup>1</sup> , Soraia Lobo-Martins1,2, Marta Martins2 and Luís Costa1,2\*

**References**

[1] Z. Jin, "Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond," *Curr Oncol,* pp. S33-S42, 2019 November.

vol. 26, November 2019.

D. R. L. K. T. J. A. S. S. J. U. Heinemann V, "FOLFIRI plus cetuximab versus FOLFIRI plus

vol. 15, p. 1065–75, 2014.

[2] M. Lee and J. Loree, "Current and emerging biomarkers in metastatic colorectal cancer," *Current Oncology,*

*DOI: http://dx.doi.org/10.5772/intechopen.93978*

*Landscape of Current Targeted Therapies for Advanced Colorectal Cancer*

W. P. Spano JP, "Impact of EGFR expression on colorectal cancer patient prognosis and survival.," *Annals of Oncology,* vol. 16, pp. 102–8, 2005.

[9] G. T. Fortunato Ciardiello, "EGFR Antagonists in Cancer Treatment," *The New England Journal of Medicine,* vol. 358, no. 11, pp. 1160–74, 2008.

[10] J.-Y. D. E. V. C. S. S. K. Z. R. W. J. W. Marc Peeters, "Journal of Clinical Oncology," *Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab,* vol. 31, no. 6,

[11] S. S. J. C. J. T. R. B. M. B. Y. H. G. B. D. C. J. J. F. R. I. K. P. R. M. B.-M. M. Š. J. L. C. M. R. K. S. O. Y. T. F. X. R. S. J Y Douillard, "Final results from PRIME:

panitumumab with FOLFOX4 for firstline treatment of metastatic colorectal cancer," *Annals of Oncology,* vol. 25, no.

[12] I. B. A. M. J. T. H. J. A. F. d. B. S. D. H. L. G. S. C. S. A. H. L. A. Z. P. K. Carsten Bokemeyer, "Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer," *Journal of Clinical Oncology,* vol.

[13] K. C. L. I. F. G. N. M. C. S. S. I. M. J. C. D. T. S. S. M. Z. A. C. I. R. P. C. F. Van Cutsem E, "Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.," *Journal of Clinical Oncology,* vol. 29, pp. 2011–19,

[14] F. R. ,. M. K. ,. G. F. ,. J.-L. C. ,. J. R. H. Y. ,. K. S. O. ,. W. Y. G. Lee S.

randomized phase III study of

7, pp. 1346–55, 2014.

27, no. 5, pp. 663–71, 2009.

2011.

pp. 759–65, 2013.

[3] S. J. Lee, "c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival," *Clinical Colorectal Cancer,* vol. 17, pp. 165–9, 2018.

[4] V. W. L. D. T. K. A. V.-k. U. S. M. M. S. L. H. N. N. R. A. H. H. M. M. L. R. M.

bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, openlabel, phase 3 trial.," *Lancet Oncology,*

[5] N. D. L. H.-J. I. F. F. B. M. J. S. D. G. C. O. B. A. J. B. S. P. B. O. E. G. R. H. H. S. R. B. M. E.-K. A. W. P. B. A. M. D. Venook AP, "Effect of first-line chemotherapy combined with

cetuximab or bevacizumab on overall survival in patients with KRAS wildtype advanced or metastatic colorectal cancer.," *JAMA,* vol. 317, p. 2392, 2017.

[6] A. M. R. C.-D. S. L. M. L. C. Marta Martins, "Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All," in *Targeted Therapy of Colorectal Cancer Subtypes*, Springer, Cham, 2019,

[7] M. Y. F. A. K. H. Oda K, "A comprehensive pathway map of epidermal growth factor receptor signaling.," *Molecular Systems Biology,*

[8] L. C. A. D. M. G. D. J. B. R. A. A. B. J. M. A. M. J. R. M. P.-L. F. B. J. F. R. K. D.

vol. 1, pp. 1–17, 2005.

pp. 113–131.

**151**

1 Oncology Division, Hospital de Santa Maria, Lisbon, Portugal

2 Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

\*Address all correspondence to: luiscosta.oncology@gmail.com

† These authors contributed equally to this work.

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Landscape of Current Targeted Therapies for Advanced Colorectal Cancer DOI: http://dx.doi.org/10.5772/intechopen.93978*
